FDA Approves Cymbalta(R) For Maintenance Treatment Of Generalized Anxiety Disorder
The U.S. Food and Drug Administration has approved Cymbalta® (duloxetine HCl) for the maintenance treatment of generalized anxiety disorder (GAD) in adults, Eli Lilly and Company announced. The efficacy and safety of Cymbalta for the maintenance treatment of GAD were established in a double-blind, placebo-controlled trial. Patients with GAD who initially had responded to treatment with Cymbalta 60-120 mg/day during a 26-week open-label phase were randomly assigned to receive Cymbalta 60-120mg/day or placebo.
For the full story, Click Here







Testing by Brunswick Laboratories has determined that each Vindure 900 tablet from Vinomis Laboratories has an ORAC rating of 19,638, which is more than six times the USDA recommended daily consumption level of antioxidants. The antioxidant power of Vindure comes from a hefty dose of its three primary ingredients: over 400mg of 98% pure trans-Resveratrol, 100mg of pure Quercetin, and 400mg of red wine grape extract containing over 90% polyphenols.
A new study, led by Usha Chakravarthy of Queen’s University in Belfast, has indicated that antioxidants found in fruit and vegetables may decelerate sight loss in many elderly people. The study showed that high intake of antioxidants preserved the muscular pigments, slowing down the progression from early age-related muscular regeneration (AMD) to late AMD.